Ovarian follicular function is not altered by SARS–CoV-2 infection or BNT162b2 mRNA COVID-19 vaccination
…, O Beharier, A Moav-Zafrir, M Kabessa… - Human …, 2021 - academic.oup.com
STUDY QUESTION Does the immune response to coronavirus disease 2019 (COVID-19)
infection or the BNT162b2 mRNA vaccine involve the ovarian follicle, and does it affect its …
infection or the BNT162b2 mRNA vaccine involve the ovarian follicle, and does it affect its …
Boosting Dose of Pfizer–BioNtech mRNA Vaccine Against SARS-CoV-2 Does Not Affect Reproductive Outcomes in In-Vitro Fertilization Patients: A Cohort Study
C Adler Lazarovits, A Smadja, M Kabessa… - Journal of Women's …, 2023 - liebertpub.com
Background: Since the introduction of anti-COVID-19 mRNA vaccination, few studies have
shown that reproductive outcomes in artificial reproductive technology (ART) treatments are …
shown that reproductive outcomes in artificial reproductive technology (ART) treatments are …
Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose
…, O Vorontsov, R Frenkel, M Kabessa… - American journal of …, 2022 - Elsevier
Background Post–COVID-19 vaccine boosting is a potent tool in the ongoing pandemic.
Relevant data regarding this approach during pregnancy are lacking, which affects vaccination …
Relevant data regarding this approach during pregnancy are lacking, which affects vaccination …
Pregnancy outcomes among patients with recurrent pregnancy loss and chromosomal aberration (CA) without PGD
M Kabessa, A Harlev, M Friger, R Sergienko… - Journal of Perinatal …, 2018 - degruyter.com
Background: Recurrent pregnancy loss (RPL) is defined by two or more failed clinical
pregnancies. Three to four percent of the couples with RPL have chromosomal aberrations (CA) in …
pregnancies. Three to four percent of the couples with RPL have chromosomal aberrations (CA) in …
[HTML][HTML] Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose
…, L Tsaitlin-Mor, HA Kam, R Frenkel, M Kabessa… - JCI insight, 2023 - ncbi.nlm.nih.gov
BACKGROUND. To minimize COVID-19 pandemic burden and spread, 3-dose vaccination
campaigns commenced worldwide. Since patients who are pregnant are at increased risk for …
campaigns commenced worldwide. Since patients who are pregnant are at increased risk for …
Boosting maternal and neonatal anti SARS-CoV-2 humoral immunity using a third mRNA vaccine dose
…, L Tsaitlin-Mor, HA Kam, R Fraenkel, M Kabessa… - 2022 - researchsquare.com
Importance: To minimize COVID-19 pandemic burden and spread, third booster dose
vaccination campaigns commenced worldwide. Since pregnant patients are at increased risk for …
vaccination campaigns commenced worldwide. Since pregnant patients are at increased risk for …
New Frontiers in RPL Research and Treatment
…, A Porgador, G Holcberg, M Kabessa - … Loss: Evidence-Based …, 2016 - Springer
In the RPL field, some aspects including evaluation, diagnosis, and treatment have been
controversial for many years. Research lacks randomized clinical trials as well as multicenter …
controversial for many years. Research lacks randomized clinical trials as well as multicenter …
[BOOK][B] Recurrent pregnancy loss
As a consequence, patients suffering from RPL can be very frustrated, and the inaccessible
nature of professional evaluation and treatment due to the very few specialized RPL clinics …
nature of professional evaluation and treatment due to the very few specialized RPL clinics …
[BOOK][B] Recurrent pregnancy loss
M Arora, N Mukhopadhaya - 2018 - books.google.com
This new edition is a comprehensive guide to recurrent pregnancy loss for practising
gynaecologists. Divided into ten sections, the book begins with a brief overview of the topic, …
gynaecologists. Divided into ten sections, the book begins with a brief overview of the topic, …
[CITATION][C] Boosting maternal and neonatal anti SARS-CoV-2 humoral immunity using a third mRNA vaccine dose (preprint)
…, L Tsaitlin-Mor, HA Kam, R Fraenkel, M Kabessa… - 2022
